太景TG-2349, Furaprevir: Rapid virologic response 92% (合併干擾素與雷巴威治療)

F*太景慢性C肝用藥EASL秀成果 2016年04月18日09:12 F*太景今天在重大訊息公告，受邀至歐洲肝臟研究協會EASL(European Association for the Study of the Liver)於西班牙巴塞隆納舉辦的國際肝病醫學會議(The Liver Congress)發表其自主研發的新藥－慢性C型肝炎蛋白「酉每」抑制劑伏拉瑞韋(TG-2349, Furaprevir)的二期臨床試驗初步結果。太景表示，二期臨床研究數據顯示，伏拉瑞韋安全性與耐受性佳，對未曾接受治療的基因 1、2、4、6型慢性C型肝炎病患均具療效，在合併健保給付的干擾素與雷巴威林後， 對基因1b的病患，RVR(Rapid virologic response)高達92%以上，即有92%的受試 者於治療 4 週後，血清中的 C 型肝炎 RNA 病毒量即檢測不到。（財經中心／台北報導）

Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C/ Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon‐alfa and ribavirin—the current standard of care. This assessment is being used to individualize treatment duration, which is currently recommended as 48 weeks in patients infected with HCV genotype 1 (G1) and 24 weeks in those infected with HCV G2 or G3.